Robert Dreicer

11.5k total citations · 3 hit papers
179 papers, 8.3k citations indexed

About

Robert Dreicer is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Robert Dreicer has authored 179 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Pulmonary and Respiratory Medicine, 76 papers in Surgery and 65 papers in Oncology. Recurrent topics in Robert Dreicer's work include Renal cell carcinoma treatment (68 papers), Bladder and Urothelial Cancer Treatments (68 papers) and Urinary and Genital Oncology Studies (41 papers). Robert Dreicer is often cited by papers focused on Renal cell carcinoma treatment (68 papers), Bladder and Urothelial Cancer Treatments (68 papers) and Urinary and Genital Oncology Studies (41 papers). Robert Dreicer collaborates with scholars based in United States, Spain and India. Robert Dreicer's co-authors include Brian I. Rini, Paul Elson, Ronald M. Bukowski, Laura S. Wood, Bruce J. Roth, Jorge A. García, Guru Sonpavde, Matthew D. Galsky, Joaquim Bellmunt and George Wilding and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Robert Dreicer

178 papers receiving 8.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

2009 690 citations Jennifer S. Ko, Arnold H. Zea et al. Clinical Cancer Research profile →
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

2017 613 citations Robert Dreicer, Seth P. Lerner et al. profile →
Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy

2011 457 citations Matthew D. Galsky, Guru Sonpavde et al. Journal of Clinical Oncology profile →

Peers

Robert Dreicer

SURGE

ONCOL

PRM

Lance C. Pagliaro United States

Aristotelis Bamias Greece

Christine Théodore France

Jens Bedke Germany

Sandrine Marréaud Belgium

Anders Jakobsen Denmark

Sandy Srinivas United States

Gwénaëlle Gravis France

Otilia Dalesio Netherlands

Li Zhang China

Lance C. Pagliaro United States

Robert Dreicer

2.1k ×0.5

SURGE

2.1k ×0.6

ONCOL

2.4k ×0.8

PRM

1.6k ×0.7

1.0k ×0.9

Citations per year, relative to Robert Dreicer Robert Dreicer (= 1×) peers Lance C. Pagliaro

Countries citing papers authored by Robert Dreicer

Since Specialization

Citations

This map shows the geographic impact of Robert Dreicer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Dreicer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Dreicer more than expected).

Fields of papers citing papers by Robert Dreicer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Dreicer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Dreicer. The network helps show where Robert Dreicer may publish in the future.

Co-authorship network of co-authors of Robert Dreicer

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Dreicer. A scholar is included among the top collaborators of Robert Dreicer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Dreicer. Robert Dreicer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Najjar, Yana G., Kriti Mittal, Paul Elson, et al.. (2014). A 2weeks on and 1week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. European Journal of Cancer. 50(6). 1084–1089. 89 indexed citations

Dinney, Colin P., Donna E. Hansel, David J. McConkey, et al.. (2014). Novel neoadjuvant therapy paradigms for bladder cancer: Results from the National Cancer Center Institute Forum. Urologic Oncology Seminars and Original Investigations. 32(8). 1108–1115. 22 indexed citations

Zhou, Ning, Kamini Singh, Maria Carmen Mir, et al.. (2013). The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo. Clinical Cancer Research. 19(7). 1717–1728. 76 indexed citations

Cooney, Matthew M., Charles Nock, Joseph A. Bokar, et al.. (2012). Phase I trial of pomalidomide given for patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 70(5). 755–761. 7 indexed citations

Galsky, Matthew D., William Oh, Joaquim Bellmunt, et al.. (2011). Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Annals of Oncology. 23(2). 406–410. 210 indexed citations

Ching, Christina B., Mohammed A. Amin, Raymond R. Tubbs, et al.. (2011). HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization. Modern Pathology. 24(8). 1111–1119. 83 indexed citations

Ko, Jennifer S., Arnold H. Zea, Brian I. Rini, et al.. (2009). Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients. Clinical Cancer Research. 15(6). 2148–2157. 690 indexed citations breakdown →

Dreicer, Robert, et al.. (2008). Everolimus for Advanced Renal Cell Carcinoma. Journal watch. 2008. 8 indexed citations

George, Saby, Robert Dreicer, Tong Shen, et al.. (2008). Phase I/II Trial of 5-Fluorouracil and a Noncytotoxic Dose Level of Suramin in Patients with Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 6(2). 79–85. 10 indexed citations

10.

Dreicer, Robert, et al.. (2007). Why Do Obese Men Have Lower PSA Concentrations. Journal watch. 2007. 2 indexed citations

11.

Rini, Brian I., Ila Tamaskar, Laura S. Wood, et al.. (2007). Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. JNCI Journal of the National Cancer Institute. 99(1). 81–83. 283 indexed citations

12.

Dreicer, Robert. (2007). Lenalidomide: Immunomodulatory, antiangiogenic, and clinical activity in solid tumors. Current Oncology Reports. 9(2). 120–123. 5 indexed citations

13.

George, Saby, Thomas E. Hutson, Tarek Mekhail, et al.. (2007). Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma. Cancer Chemotherapy and Pharmacology. 62(2). 347–354. 11 indexed citations

14.

Dreicer, Robert, Shuli Li, Judith Manola, et al.. (2007). Phase 2 trial of epothilone B analog BMS‐247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800). Cancer. 110(4). 759–763. 61 indexed citations

15.

Beer, Tomasz M., Catherine M. Tangen, Craig R. Nichols, et al.. (2006). Southwest oncology group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer. 106(12). 2624–2629. 23 indexed citations

16.

Dreicer, Robert, Eric A. Klein, Paul Elson, et al.. (2005). Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer. Urologic Oncology Seminars and Original Investigations. 23(2). 82–86. 25 indexed citations

17.

Rosen, Lee S., Anthony Howell, Lester Porter, et al.. (2001). Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 91(7). 1191–1200. 398 indexed citations

18.

Dreicer, Robert, Sheila S. Galbraith, Charles S. Davis, & William A. See. (1997). Surgical resection of metastatic renal cell carcinoma: The University of Iowa experience. Urologic Oncology Seminars and Original Investigations. 3(3). 99–101. 9 indexed citations

19.

Witte, Robert S., Paul Elson, Bartholomew R. Bono, et al.. (1997). Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma.. Journal of Clinical Oncology. 15(2). 589–593. 155 indexed citations

20.

Clamon, Gerald H., Charles E. Riggs, Robert Dreicer, & Raymond J. Hohl. (1995). Phase II trial of edatrexate in patients with metastatic colorectal cancer. Investigational New Drugs. 13(4). 359–361. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact